176 related articles for article (PubMed ID: 37874652)
1. Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.
Zhao N; Kabotyanski EB; Saltzman AB; Malovannaya A; Yuan X; Reineke LC; Lieu N; Gao Y; Pedroza DA; Calderon SJ; Smith AJ; Hamor C; Safari K; Savage S; Zhang B; Zhou J; Solis LM; Hilsenbeck SG; Fan C; Perou CM; Rosen JM
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37874652
[TBL] [Abstract][Full Text] [Related]
2. Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.
Zhao N; Kabotyanski EB; Saltzman AB; Malovannaya A; Yuan X; Reineke LC; Lieu N; Gao Y; Pedroza DA; Calderon SJ; Smith AJ; Hamor C; Safari K; Savage S; Zhang B; Zhou J; Solis LM; Hilsenbeck SG; Fan C; Perou CM; Rosen JM
bioRxiv; 2023 Sep; ():. PubMed ID: 37808840
[TBL] [Abstract][Full Text] [Related]
3. Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors.
Gerson-Gurwitz A; Young NP; Goel VK; Eam B; Stumpf CR; Chen J; Fish S; Barrera M; Sung E; Staunton J; Chiang GG; Webster KR; Thompson PA
Front Oncol; 2021; 11():766298. PubMed ID: 34900714
[TBL] [Abstract][Full Text] [Related]
4. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
6. The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers.
Moens S; Zhao P; Baietti MF; Marinelli O; Van Haver D; Impens F; Floris G; Marangoni E; Neven P; Annibali D; Sablina AA; Amant F
Sci Rep; 2021 Feb; 11(1):3176. PubMed ID: 33542435
[TBL] [Abstract][Full Text] [Related]
7. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts.
Wu Y; Yi Z; Li J; Wei Y; Feng R; Liu J; Huang J; Chen Y; Wang X; Sun J; Yin X; Li Y; Wan J; Zhang L; Huang J; Du H; Wang X; Li Q; Ren G; Li H
Theranostics; 2022; 12(10):4564-4580. PubMed ID: 35832090
[No Abstract] [Full Text] [Related]
8. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
10. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
11. Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.
Sceneay J; Goreczny GJ; Wilson K; Morrow S; DeCristo MJ; Ubellacker JM; Qin Y; Laszewski T; Stover DG; Barrera V; Hutchinson JN; Freedman RA; Mittendorf EA; McAllister SS
Cancer Discov; 2019 Sep; 9(9):1208-1227. PubMed ID: 31217296
[TBL] [Abstract][Full Text] [Related]
12. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
13. Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer.
Bagati A; Kumar S; Jiang P; Pyrdol J; Zou AE; Godicelj A; Mathewson ND; Cartwright ANR; Cejas P; Brown M; Giobbie-Hurder A; Dillon D; Agudo J; Mittendorf EA; Liu XS; Wucherpfennig KW
Cancer Cell; 2021 Jan; 39(1):54-67.e9. PubMed ID: 33385331
[TBL] [Abstract][Full Text] [Related]
14. A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer.
Cencic R; Im YK; Naineni SK; Moustafa-Kamal M; Jovanovic P; Sabourin V; Annis MG; Robert F; Schmeing TM; Koromilas A; Paquet M; Teodoro JG; Huang S; Siegel PM; Topisirovic I; Ursini-Siegel J; Pelletier J
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2318093121. PubMed ID: 38232291
[TBL] [Abstract][Full Text] [Related]
15. ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.
Wang G; Romero Y; Thevarajan I; Zolkiewska A
Oncoimmunology; 2023; 12(1):2158006. PubMed ID: 36545255
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS
Cancer Immunol Res; 2017 Oct; 5(10):871-884. PubMed ID: 28848054
[TBL] [Abstract][Full Text] [Related]
18. A hierarchical tumor-targeting strategy for eliciting potent antitumor immunity against triple negative breast cancer.
Lin M; Cai Y; Chen G; Zhong H; Li B; Li T; Xiao Z; Shuai X
Biomaterials; 2023 May; 296():122067. PubMed ID: 36854221
[TBL] [Abstract][Full Text] [Related]
19. BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.
Wang X; Feng M; Xiao T; Guo B; Liu D; Liu C; Pei J; Liu Q; Xiao Y; Rosin-Arbesfeld R; Shi Y; Zhou Y; Yang M; Feng YX; Jiang Y; Shao Z; Yu K; Zhu D
Oncogene; 2021 Apr; 40(16):2982-2997. PubMed ID: 33767438
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
